UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 23, 2020
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware
1-3619
13-5315170
(State or other
(Commission File
(I.R.S. Employer
jurisdiction of
Number)
Identification No.)
incorporation)
235 East 42nd Street
10017
New York,
New York
(Zip Code)
(Address of principal executive offices)
Registrant s telephone number, including area code:
(212) 733-2323
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.05 par value
PFE
New York Stock Exchange
0.250% Notes due 2022
PFE22
New York Stock Exchange
1.000% Notes due 2027
PFE27
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders
(a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 23, 2020.
(b) Shareholders voted on the matters set forth below.
1. The nominees for election to the Company s Board of Directors set forth in Item 1 to the Company s Proxy Statement filed with the U.S. Securities and Exchange Commission on March 13, 2020 were elected to hold office until the Company s next Annual Meeting of Shareholders, based upon the following votes:
Nominee
Votes For
Votes Against
Abstentions
Broker non-vote
Ronald E. Blaylock
3,838,566,625
56,381,770
13,596,621
812,957,533
Albert Bourla
3,694,789,467
186,110,953
27,646,791
812,957,533
W. Don Cornwell
3,804,895,768
90,180,287
13,471,156
812,957,533
Joseph J. Echevarria
3,598,011,274
298,143,259
12,392,678
812,957,533
Scott Gottlieb
3,875,072,029
20,928,717
12,546,465
812,957,533
Helen H. Hobbs
3,874,592,839
22,787,784
11,166,587
812,957,533
Susan Hockfield
3,879,605,512
18,539,362
10,402,337
812,957,533
James M. Kilts
3,257,924,746
638,358,601
12,263,863
812,957,533
Dan R. Littman
3,870,004,992
26,060,961
12,481,257
812,957,533
Shantanu Narayen
3,865,221,904
30,969,956
12,355,350
812,957,533
Suzanne Nora Johnson
3,733,297,401
164,478,705
10,771,104
812,957,533
James Quincey
3,871,405,786
25,379,651
11,761,773
812,957,533
James C. Smith
3,852,504,316
43,772,088
12,270,806
812,957,533
2. The proposal to ratify the selection of KPMG LLP as the Company s independent registered public accounting firm for the 2020 fiscal year was approved based upon the following votes:
Votes for approval
4,517,781,714
Votes against
189,300,865
Abstentions
14,422,165
Broker non-votes
n/a
3. The proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers was approved based upon the following votes:
Votes for approval
3,687,626,065
Votes against
193,562,262
Abstentions
27,358,009
Broker non-votes
812,957,533
4. The shareholder proposal regarding right to act by written consent was not approved based upon the following votes:
Votes for approval
614,675,966
Votes against
3,262,924,232
Abstentions
30,946,935
Broker non-votes
812,957,533
5. The shareholder proposal regarding enhancing proxy access was not approved based upon the following votes:
Votes for approval
1,172,526,227
Votes against
2,707,722,195
Abstentions
28,298,711
Broker non-votes
812,957,533
6. The shareholder proposal regarding report on lobbying activities was not approved based upon the following votes:
Votes for approval
795,529,692
Votes against
3,070,923,866
Abstentions
42,093,653
Broker non-votes
812,957,533
7. The shareholder proposal regarding independent chair policy was not approved based upon the following votes:
Votes for approval
1,320,327,998
Votes against
2,562,531,292
Abstentions
25,687,720
Broker non-votes
812,957,533
8. The shareholder proposal regarding gender pay gap was not approved based upon the following votes:
Votes for approval
1,416,237,122
Votes against
2,296,745,539
Abstentions
195,562,451
Broker non-votes
812,957,533
9. Susan Desmond-Hellmann was elected to the Company s Board of Directors to hold office until the Company s next Annual Meeting of Shareholders, based upon the following votes:
Nominee
Votes For
Votes Against
Abstentions
Broker non-vote
Susan Desmond-Hellmann
3,585,622,194
23,967,398
36,831,173
1,050,149,944
(c) Not applicable
(d) Not applicable
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.